At a Glance
- Companies: TetraScience; Thermo Fisher Scientific Inc.
- Location: Boston, Massachusetts, USA
- Deal value: Undisclosed; focus on high‑value workflows at select global pharmas
- Focus area: Scientific data harmonisation, AI‑native workflows for R&D and manufacturing
- Next steps: Integrate Thermo instruments with Tetra platform for AI use cases at customer sites
What happened?
TetraScience and Thermo Fisher Scientific have announced a collaboration to accelerate AI adoption in biopharma R&D and manufacturing by transforming fragmented laboratory data into AI‑native form and developing intelligent workflows at scale. The partnership targets high‑value scientific processes at select global pharmaceutical organisations already using their combined solutions.
Why does it matter?
Biopharma R&D costs are soaring amid complex therapies, but fragmented lab data—locked in incompatible vendor formats—hampers AI’s potential for productivity gains. TetraScience’s vendor‑agnostic Scientific Data Foundry standardises data from disparate instruments, while Tetra AI surfaces insights; paired with Thermo’s leading instrumentation and informatics, this enables reproducibility, throughput and scalability across discovery, development and manufacturing.
Who’s behind it?
TetraScience provides the Scientific Data and AI Platform, including a Data Foundry for cloud harmonisation and Use Case Factory for workflows, trusted by top pharmas and partners like NVIDIA and Databricks. Thermo Fisher is the world leader in serving science, with AI capabilities across life sciences, diagnostics and applied markets.
How was it achieved?
TetraScience will integrate Thermo’s instruments and software into its platform, unlocking scaleable data contextualisation for Tetra AI to power automated workflows, real‑time analysis and cross‑domain insights. Joint efforts target reproducibility, quality control and decision‑making in high‑throughput settings.
What’s next?
The partners will deploy integrated solutions at customer sites, industrialising AI workflows and fostering broader adoption across biopharma. TetraScience CEO Patrick Grady sees it as building an “AI‑native scientific operating system” that learns from every experiment.
What are people saying?
TetraScience CEO Patrick Grady said the collaboration replaces “isolated processes” with compounding AI capabilities. Thermo Fisher VP Sean Baumann noted it strengthens automation “at scale in the laboratory” to accelerate breakthroughs. Grady called it a “pivotal moment” for life sciences AI.